117559-88-3

Basic information

• Product Name: Benzeneacetic acid, 5-Methoxy-2-nitro-, ethyl ester
• Synonyms: Benzeneacetic acid, 5-Methoxy-2-nitro-, ethyl ester;ethyl 2-(5-methoxy-2-nitrophenyl)ethanoate
• CAS NO: 117559-88-3
• Molecular Formula: C₁₁H₁₃NO₅
• Molecular Weight: 239.22462
• Mol File: 117559-88-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzeneacetic acid, 5-Methoxy-2-nitro-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, 5-Methoxy-2-nitro-, ethyl ester(117559-88-3)
• EPA Substance Registry System: Benzeneacetic acid, 5-Methoxy-2-nitro-, ethyl ester(117559-88-3)

Safety Data

• Hazardous Substances Data: 117559-88-3(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 20876-29-3 2-(5-methoxy-2-nitrophenyl)acetic acid 
• 74-88-4 methyl iodide 
• 100-17-4 para-methoxynitrobenzene 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 21857-42-1 2-(5-methoxy-2-nitrophenyl)ethan-1-ol 
• 124043-85-2 2-(2-amino-5-methoxyphenyl)ethyl alcohol 
• 20876-29-3 2-(5-methoxy-2-nitrophenyl)acetic acid 
• 1310481-79-8 ethyl 2-(5-methoxy-2-nitrophenyl)-2-butenoate 
• 117559-77-0 ethyl 2-benzamido-5-methoxyphenylacetate 
• 106501-76-2 ethyl 2-acetamido-5-methoxyphenylacetate 
• 106501-80-8 N-benzoyl-2-(carbethoxymethyl)-p-benzoquinone imine dimethyl ketal 
• 106501-79-5 N-acetyl-2-(carbethoxymethyl)-p-benzoquinone imine dimethyl ketal 

Relevant articles and documents

TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS

The present invention relates to 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepine derivatives of general formula (I) and/or salts thereof and/or geometric isomers thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or biologically active metabolites thereof and/or prodrugs thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof which are centrally and/or peripherally acting V1a receptor modulators, particularly V1a receptor antagonists. Additional subject of the present invention is the process for the preparation of the compounds and the intermediates of the preparation process as well. The invention also relates to the pharmaceutical compositions containing the compounds or together with one or more other active substances, as well as to the use in the treatment and/or prophylaxis of a disease or condition associated with V1a receptor function.